Our Advisory Boards include some of the most respected professionals in the industry, including CEOs, Nobel laureates, and other industry luminaries.

• Burrill Life Sciences III Advisory Board
• Burrill Life Sciences II Advisory Board
• Burrill Biotechnology Advisory Board
• Burrill Agbio Advisory Board
• Burrill Nutraceuticals Advisory Board

 

Burrill Life Sciences III Advisory Board

Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry

Carl Feldbaum—President Emeritus, Biotechnology Industry Organization.

Frederick Frank—Vice Chairman and Director, Lehman Brothers.

Martin Gerstel—Chairman of Compugen, Keddem Bioscience and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation

Lee Hood—President of The Institute for Systems Biology

David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and Hospitals

George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona State University; former CSTO and head of R&D, SmithKline Beecham

Tommy Thompson—Former Secretary of Health & Human Services; former Governor of Wisconsin; BLSCF II Advisory Board

Burrill Life Sciences II Advisory Board

 

Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director,
Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate
in Chemistry

Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison

Jonathan Dordick—The Howard P. Isermann Professor in the Departments of Chemical and
Biological Engineering and Biology, Center for Biotechnology and Interdisciplinary Studies,
Rensselaer Polytechnic Institute

Alain Enthoven—Marriner S. Eccles Professor of Public and Private Management Emeritus at
the Stanford Graduate School of Business

Frederick Frank—Vice Chairman and Director, Lehman Brothers

Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex

Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman
of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation

Jeff Goldsmith—President, Health Futures

David M. Lawrence—Chairman and CEO (retired), Kaiser Foundation Health Plan and
Hospitals

Eric Lander—Director, Broad Institute of MIT and Harvard

Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately
held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine
and rhinitus.

George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona
State University; former CSTO and head of R&D, SmithKline Beecham

L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company; Managing Director
of Galen Partners, a late-stage healthcare private equity fund

Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)

Burrill Biotechnology Advisory Board

 

Paul Berg—Cahill Professor in Biochemistry, Emeritus, Stanford University; Director, Emeritus, Beckman Center for Molecular and Genetic Medicine at Stanford; Nobel Laureate in Chemistry

Sean Carroll—Investigator, Howard Hughes Medical Institute; Professor of Genetics, University
of Wisconsin, Madison

Frederick Frank—Vice Chairman and Director, Lehman Brothers

Paul Freiman—President and CEO of Neurobiological Technologies; former Chairman and
CEO, Syntex

Martin Gerstel—Chairman of Compugen, Keddem Bioscience, and Evogene; Co-Chairman of Itamar Medical; former Co-Chairman and CEO of ALZA Corporation

Jeff Goldsmith—President, Health Futures

Eric Lander—Director, Broad Institute of MIT and Harvard

Ernest Mario, Ph.D.—Chairman, CEO of Capnia, Palo Alto, California. Capnia is a privately held pharmaceutical company utilizing carbon dioxide as a therapeutic medical gas to treat migraine and rhinitus.

George Poste—CEO, Health Technology Networks; Director, The Biodesign Institute, Arizona
State University; former CSTO and head of R&D, SmithKline Beecham

L. John Wilkerson—Founder of the Wilkerson Group, now an IBM Company and currently
Managing Director of Galen Partners, a late stage healthcare private equity fund

Keith R. Yamamoto—Professor of Cellular and Molecular Pharmacology, Executive Vice Dean
in the School of Medicine at the University of California, San Francisco (UCSF)

Burrill Agbio Advisory Board

 

Charles Arntzen—President and CEO Emeritus, Boyce Thompson Institute for Plant Research; Regent’s Professor, Arizona Biodesign Institute, Arizona State University; member of President George W. Bush’s Council of Advisors on Science and Technology (PCAST)

Dennis Purcell—Senior Managing Director, Aisling Capital and Perseus-Soros Management, LLC; former Managing Director of Life Sciences Investment Banking, Chase Hambrecht & Quist

Marc Zabeau—CEO Methexis Genomics; Scientific Advisor, Department of Plant Systems Biology, Flemish Interuniversity Institute for Biotechnology

Burrill Nutraceuticals Advisory Board

Charles Arntzen—President and CEO Emeritus, Boyce Thompson Institute for Plant Research; Regent’s Professor, Arizona Biodesign Institute, Arizona State University; member of President George W. Bush’s Council of Advisors on Science and Technology (PCAST)

Peter Barton Hutt—Senior Counsel, Covington & Burling, a Washington-based law firm
specializing in food and drug law; former Chief Counsel of the FDA; member of the Institute of
Medicine; teaches Food and Drug Law course at Harvard Law

Nancy Fogg-Johnson—Technology Commercialization Consultant, Technology and Business Ventures; Co-founder of Efficas and NutraGenomics; Former Vice President Biotechnology/ Food Ingredients R&D and Vice President Personal Care Drugs, Bayer; former Vice President, Basic Research, Campbell Soup; former Vice President, R&D and QA, Nabisco Grocery Company

Jordan Gutterman— Distinguished Professor of Medicine, University of Texas, M.D. Anderson
Cancer Center, Houston

Susan Kay Harlander—President, Biorational Consultants; Principal, BTSafety, LLC; former Vice President of Green Giant and Progresso R&D and Agricultural Research at The Pillsbury Company; former Vice President of Biotechnology Development, The Pillsbury Company

Peter Mattson—Founder and Chairman, MATTSON, Largest New Product Development Company in the US Food & Beverage Industry

Charles Muscoplat— Vice President for Statewide Strategic Resource Development; McKnight Presidential Leadership Endowed Chair; Professor of Medicine, Microbiology, Food Science, and Nutrition